Cannabadiol (CBD) products have been in the news a lot recently, but what does it take to bring a CBD product to market for an unmet medical need? This webinar discusses development considerations for CBD and other cannabis-derived products from a clinical, preclinical (pharmacology/toxicology), CMC, and regulatory perspective. The webinar also reviews challenges and lessons learned from the development and approval of Epidiolex of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years of age and older.